Physician profile
Michael Jesinger
NPI 1013352368
$1,737.08
in general payments reported to CMS, 2019-2025
15 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $46.08 · 2021: $263 · 2022: $15.29 · 2023: $264 · 2024: $490 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $333.81 | 2024-2025 | |
| Abbott Laboratories | $295.02 | 2021-2024 | Aveir |
| Biotronik INC. | $274.21 | 2023-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Novartis Pharmaceuticals Corporation | $233.53 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $151.39 | 2020-2022 | |
| Ekos Corporation | $130.85 | 2019 | |
| Impulse Dynamics (USA) INC. | $113.49 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.78 | 2024 | Lifevest |
| Amgen INC. | $51.05 | 2019-2020 | |
| Bridgebio Pharma, INC. | $29.65 | 2025 | Attruby |
| Boston Scientific Corporation | $18.95 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2021 | |
| Pfizer INC. | $11.89 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.